PerkinElmer Inc., a global leader committed to innovating for a healthier world, announced that the company has completed the sale of its Medical Imaging business to Varex Imaging Corporation.
Caribou Biosciences and DuPont Pioneer Develop New Method to Comprehensively Map the Off-Target Activity of CRISPR-Cas9 Across Entire Genomes
Caribou Biosciences Inc. announced the Nature Methods publication describing SITE-Seq, a new method for comprehensively mapping CRISPR-Cas9 cleavage sites across the genome of any organism. When compared against other off-target analysis techniques, SITE-Seq detected potential off-target cleavage sites with a higher degree of resolution.
Study in The Journal of the American Osteopathic Association Highlights Risk Factors, Treatment Protocols CHICAGO, May 1, 2017 /PRNewswire-USNewswire/ –Results from a clinical review published in The Journal of the American Osteopathic Association find nearly 1 billion people worldwide may have deficient or insufficient levels of vitamin D due to chronic disease […]
Neurotrope Inc. said on Monday that the smaller dose of its experimental Alzheimer’s drug met the main goal in a small mid-stage study, but the company’s shares more than halved as investors were not impressed with the data.
London-based GlaxoSmithKline announced that it is investing $139 million into its manufacturing location in Rockville, Md.
Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery
Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.
Danish drugmaker Novo Nordisk A/S has settled a U.S. Department of Justice probe into the company’s marketing activities for its diabetes drugs that allegedly included paybacks to doctors and disguising sales people as medical educators, Bloomberg reported.
North Carolina-based Parion Sciences snagged a deal worth up to $535 million from Shire for its experimental dry eye disease treatment, P-321.
The U.S. Food and Drug Administration granted Takeda Pharmaceutical’s Alunbrig (brigatinib) accelerated approval for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in patients who have progressed on or are intolerant to crizotinib.